BEDFORD, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that aPROMISE, its AI-enabled FDA-cleared medical device software, is now available on the syngo.via platform, from Siemens Healthineers, one of the leading workstation systems. Siemens Healthineers will be demonstrating the integrated solution at the upcoming annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Toronto June 8-11, 2024.
aPROMISE is a deep learning-enabled, FDA-cleared medical device software that provides quantitative total disease burden on PSMA PET/CT images, including those obtained using PYLARIFY® (piflufolastat F 18) PET/CT. In planned prospective and independent validation studies, aPROMISE has demonstrated rapid lesion detection and standardized quantitative tumor burden biomarkers in PSMA PET/CT imaging. Recent clinical studies have shown that total quantitative burden with aPROMISE supports patient selection for PSMA radioligand therapy (RLT) and automates monitoring response over time.
“Given the expanding treatment options for advanced prostate cancer, especially PSMA-targeted radioligand therapy, there is an increasing need to understand treatment eligibility and response using PSMA PET. The deep learning-enabled analysis of PSMA PET/CT images by aPROMISE can generate clinically relevant imaging biomarkers, potentially expanding the clinical utility of PSMA PET in managing prostate cancer," said Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota.
The Siemens Healthineers portfolio of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners play a central role in clinical decision-making and therapy evaluation. Siemens Healthineers’ syngo.via is the vendor-neutral imaging software platform for 2D, 3D, and 4D reading and advanced visualization of medical images. The aPROMISE solution will be integrated on the syngo.via platform, one of the leading workstation systems, and will be available via its OpenApps Digital Marketplace. This will further facilitate nuclear medicine clinical workflow across the PET sites in the U.S.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Back to HCB News
